Literature DB >> 20175768

Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis.

L Vannella1, E Lahner, J Osborn, C Bordi, M Miglione, G Delle Fave, B Annibale.   

Abstract

BACKGROUND: Atrophic gastritis, involving the gastric body mucosa, predisposes to gastric neoplastic lesions (GNL). However, regular gastroscopic-histological follow-up for GNL is not recommended for patients with atrophic gastritis. AIM: To evaluate risk factors for the progression to GNL in a cohort of patients with atrophic gastritis.
METHODS: A total of 300 patients with atrophic gastritis [205 women, aged 54 (18-78) years] underwent gastroscopy with six gastric antrum and body biopsies. All patients had at least one follow-up gastroscopy/histology at an interval of at least 1 year after the atrophic gastritis diagnosis. Baseline clinical and histological features were analysed as risk factors for the development of GNL by Cox-regression.
RESULTS: During a median follow-up of 4.3 (1-16.5) years, 15 GNL were detected in 14 of the 300 patients with atrophic gastritis: three were gastric cancer, whereas 12 were non-invasive neoplasia. The annual incidence for GNL was 1%. Cox-regression analysis identified the following risk factors: age over 50 years (HR 8.8, 95%CI 1.2-68.4), atrophic pangastritis (HR 4.5, 95% CI 1.5-14.1) and severe intestinal metaplasia in the gastric body (HR 4.0, 95% CI 1.3-11.8).
CONCLUSIONS: Atrophic pangastritis, severe body intestinal metaplasia and/or age over 50 years increase the risk for developing GNL in patients with atrophic gastritis. In this subset of patients, an endoscopic-histological follow-up for GNL surveillance may be worthwhile.

Entities:  

Mesh:

Year:  2010        PMID: 20175768     DOI: 10.1111/j.1365-2036.2010.04268.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  24 in total

1.  Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment.

Authors:  Massimo Rugge; Matteo Fassan; Marco Pizzi; Fabio Farinati; Giacomo Carlo Sturniolo; Mario Plebani; David Y Graham
Journal:  World J Gastroenterol       Date:  2011-11-07       Impact factor: 5.742

Review 2.  Diagnosis and management of pernicious anemia.

Authors:  Bruno Annibale; Edith Lahner; Gianfranco Delle Fave
Journal:  Curr Gastroenterol Rep       Date:  2011-12

3.  Methylation-dependent activation of CDX1 through NF-κB: a link from inflammation to intestinal metaplasia in the human stomach.

Authors:  Tilman T Rau; Anja Rogler; Myrjam Frischauf; Andreas Jung; Peter C Konturek; Arno Dimmler; Gerhard Faller; Bettina Sehnert; Wael El-Rifai; Arndt Hartmann; Reinhard E Voll; Regine Schneider-Stock
Journal:  Am J Pathol       Date:  2012-06-27       Impact factor: 4.307

4.  How Do We Manage Gastric Intestinal Metaplasia? A Survey of Clinical Practice Trends for Gastrointestinal Endoscopists in the United States.

Authors:  R Brooks Vance; Nisa Kubiliun; Kerry B Dunbar
Journal:  Dig Dis Sci       Date:  2016-03-17       Impact factor: 3.199

5.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Virchows Arch       Date:  2011-12-22       Impact factor: 4.064

6.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Endoscopy       Date:  2011-12-23       Impact factor: 10.093

Review 7.  Autoimmune gastritis: Pathologist's viewpoint.

Authors:  Irene Coati; Matteo Fassan; Fabio Farinati; David Y Graham; Robert M Genta; Massimo Rugge
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 8.  Autoimmune atrophic gastritis--pathogenesis, pathology and management.

Authors:  William L Neumann; Elizabeth Coss; Massimo Rugge; Robert M Genta
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-06-18       Impact factor: 46.802

9.  Risks and Predictors of Gastric Adenocarcinoma in Patients with Gastric Intestinal Metaplasia and Dysplasia: A Population-Based Study.

Authors:  Dan Li; Marita C Bautista; Sheng-Fang Jiang; Paras Daryani; Marilyn Brackett; Mary Anne Armstrong; Yun-Yi Hung; Debbie Postlethwaite; Uri Ladabaum
Journal:  Am J Gastroenterol       Date:  2016-05-17       Impact factor: 10.864

10.  Gastric cancer in patients with type I gastric carcinoids.

Authors:  Edith Lahner; Gianluca Esposito; Emanuela Pilozzi; Gloria Galli; Vito D Corleto; Emilio Di Giulio; Bruno Annibale
Journal:  Gastric Cancer       Date:  2014-06-03       Impact factor: 7.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.